FXR also upregulates hepatic glycogen synthesis and regulates the expression of glucose transporter 4 (GLUT-4) and glucagon-like peptide 1 (GLP-1) which affects the insulin sensitivity that is closely linked to NAFLD [43]. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.